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Introduction
The TENDER clinical trial is a three-part, 5-year, phase 3
study with tocilizumab (TCZ) in active systemic JIA (sjia).
After 2 years of treatments, sjia patients who have main-
tained clinically inactive disease for 3 months are given the
option to participate in an alternative TCZ dosing regimen
aimed at spacing the infusions and eventually withdrawing
TCZ.
Objectives
To describe the patients registered to participate in the
optional alternative dosing schedule in the TENDER study.
Methods
To qualify for the optional alternative dosing schedule
(OADS), patients had to be in the study for 2 years and
have achieved ACR JIA inactive disease status. Among the
112 patients (pts) enrolled, 39 (35%) entered the optional
alternative dosing regimen. This entailed a staged prolon-
gation of the time interval between TCZ infusions from
2 weeks (standard interval) to 3 weeks, then 4 weeks, with
the option of terminating TCZ after the discontinuation of
any treatment.
Results
23 male and 16 female patients entered the OADS. Their
mean baseline characteristics were 14.2 active joints, 15.4
joints with limitation of motion (LOM), physician global
VAS score of 58.5, CHAQ-DI score of 1.62 and ESR of
56.8; 15 had fever. Of these 39 patients, 13 patients lost
clinically inactive disease status while on the OADS. In
these 13 patients, the time to loss of inactive disease sta-
tus ranged from 1.4 to 16.8 months from initiation of the
OADS (n = 4 on 3 weekly dosing, n = 6 on 4 weekly dos-
ing, n = 3 off TCZ). Risk of losing inactive disease status
on OADS was similar in patients treated with MTX
(6/16, 37.5% flared) and in those not receiving MTX
(7/23, 30% flared). Inactive disease status was maintained
in 26 of the 39 patients entering the OADS. Present dos-
ing intervals were every 3 weeks in 3 pts and every
4 weeks in 14 pts; 9 pts have been able to discontinue
TCZ (range of time since discontinuation: 3.6-13.4
months). At baseline, these 9 pts were clinically similar to
other pts entering the OADS (mean characteristics: age
9.1 years, 10.9 active joints, 10.9 joints with LOM, physi-
cian global VAS score of 45.4, CHAQ-DI score of 1.42,
ESR of 47.2; 4 pts with fever at baseline).
Conclusion
Patients with sjia who maintain clinically inactive disease
status can progressively space TCZ infusions, with one-
fourth of them able to discontinue all treatments, includ-
ing TCZ.
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